EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy

Asiye Busra Boz Er, Helen M Sheldrake iD, Mark Sutherland iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25147946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Asiye Busra Boz Er und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, UK. Hauptthemen laut MEDLINE: Vemurafenib, Melanoma, Drug Resistance, Neoplasm, Snake Venoms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The ministry of National Education Turkey, Ministry of National Education-YLSY program—Turkey.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic melanoma, a deadly form of skin cancer, often develops resistance to the BRAF inhibitor drug vemurafenib, highlighting the need for understanding the underlying mechanisms of resistance and exploring potential therapeutic strategies targeting integrins and TGF-β signalling. In this study, the role of integrins and TGF-β signalling in vemurafenib resistance in melanoma was investigated, and the potential of combining vemurafenib with cilengitide as a therapeutic strategy was investigated. In this study, it was found that the transcription of PAI1 and p21 was induced by acquired vemurafenib resistance, and ITGA5 levels were increased as a result of this resistance. The transcription of ITGA5 was mediated by the TGF-β pathway in the development of vemurafenib resistance. A synergistic effect on the proliferation of vemurafenib-resistant melanoma cells was observed with the combination therapy of vemurafenib and cilengitide. Additionally, this combination therapy significantly decreased invasion and colony formation in these resistant cells. In conclusion, it is suggested that targeting integrins and TGF-β signalling, specifically ITGA5, ITGB3, PAI1, and p21, may offer promising approaches to overcoming vemurafenib resistance, thereby improving outcomes for metastatic melanoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VemurafenibMelanomaDrug Resistance, NeoplasmSnake VenomsHumansCell Line, TumorIntegrin beta3Transforming Growth Factor betaSignal TransductionCell ProliferationIntegrinsIntegrin alpha5Skin NeoplasmsCyclin-Dependent Kinase Inhibitor p21IndolesGene Expression Regulation, NeoplasticSulfonamidesAntineoplastic Agents

Stichwörter der Autor:innen

BRAFdrug resistanceintegrinmelanoma

Substanzen

VemurafenibCilengitideSnake VenomsIntegrin beta3Transforming Growth Factor betaIntegrinsIntegrin alpha5ITGB3 protein, humanCyclin-Dependent Kinase Inhibitor p21Indoles

Autor:innen und Institutionen

  • Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, UK.
  • School of Chemistry and Biosciences, University of Bradford, Bradford BD7 1DP, UK.

ORCID-Profile: Helen M Sheldrake, Mark Sutherland

Förderung

  • The ministry of National Education Turkey
  • Ministry of National Education-YLSY program—Turkey

Zitieren

APA

Boz Er, A. B., Sheldrake, H. M., & Sutherland, M. (2024). Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147946

Vancouver

Boz Er AB, Sheldrake HM, Sutherland M. Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147946

BibTeX
@article{BozEr2024,
  author = {Boz Er, Asiye Busra and Sheldrake, Helen M and Sutherland, Mark},
  title = {Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25147946}
}
Kostenlos starten →